Jinarc Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

jinarc

otsuka pharmaceutical netherlands b.v. - tolvaptan - rene policistico, dominante autosomica - diuretici, - jinarc è indicato per rallentare la progressione di sviluppo di cisti e insufficienza renale della malattia renale policistica dominante autosomica (adpkd) negli adulti con insufficienza renale cronica della fase 1 a 3 all'inizio del trattamento con evidenza di malattia velocemente di progressione.

Jinarc 15 mg Compresse Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

jinarc 15 mg compresse

otsuka pharmaceutical (switzerland) gmbh - tolvaptanum - compresse - tolvaptanum 15 mg, hydroxypropylcellulosum, lactosum monohydricum 36.913 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, e 132 pro compresso. - rallentamento della progressione della zystenentwicklung e in caso di insufficienza renale autosomica dominante polyzystischer malattie renali - synthetika

Jinarc 30 mg Compresse Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

jinarc 30 mg compresse

otsuka pharmaceutical (switzerland) gmbh - tolvaptanum - compresse - tolvaptanum 30 mg, hydroxypropylcellulosum, lactosum monohydricum 73.826 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, e 132 pro compresso. - rallentamento della progressione della zystenentwicklung e in caso di insufficienza renale autosomica dominante polyzystischer malattie renali - synthetika

Jinarc 45 mg + 15 mg Compresse Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

jinarc 45 mg + 15 mg compresse

otsuka pharmaceutical (switzerland) gmbh - tolvaptanum - compresse - a): tolvaptanum 45 mg, hydroxypropylcellulosum, lactosum monohydricum 12.629 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, e 132 pro compresso. b): tolvaptanum 15 mg, hydroxypropylcellulosum, lactosum monohydricum 36.913 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, e 132 pro compresso. - rallentamento della progressione della zystenentwicklung e in caso di insufficienza renale autosomica dominante polyzystischer malattie renali - synthetika

Jinarc 60 mg + 30 mg Compresse Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

jinarc 60 mg + 30 mg compresse

otsuka pharmaceutical (switzerland) gmbh - tolvaptanum - compresse - a): tolvaptanum 60 mg, hydroxypropylcellulosum, lactosum monohydricum 16.838 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, e 132 pro compresso. b): tolvaptanum 30 mg, hydroxypropylcellulosum, lactosum monohydricum 73.826 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, e 132 pro compresso. - rallentamento della progressione della zystenentwicklung e in caso di insufficienza renale autosomica dominante polyzystischer malattie renali - synthetika

Jinarc 90 mg + 30 mg Compresse Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

jinarc 90 mg + 30 mg compresse

otsuka pharmaceutical (switzerland) gmbh - tolvaptanum - compresse - a): tolvaptanum 90 mg, hydroxypropylcellulosum, lactosum monohydricum 25.257 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, e 132 pro compresso. b): tolvaptanum 30 mg, hydroxypropylcellulosum, lactosum monohydricum 73.826 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, e 132 pro compresso. - rallentamento della progressione della zystenentwicklung e in caso di insufficienza renale autosomica dominante polyzystischer malattie renali - synthetika

Ibrance 75 mg Capsule rigide Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

ibrance 75 mg capsule rigide

pfizer ag - palbociclibum - capsule rigide - palbociclibum 75 mg, cellulosum microcristallinum, lactosum monohydricum 55.775 mg, carboxymethylamylum natricum a, silica colloidalis anhydrica, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 172 (flavum), e 171, drucktinte: lacca, e 171, ammoniae solutio 28 per centum, propylenglycolum, simeticonum, pro capsula, natrium 1.28 mg. - carcinoma della mammella - synthetika

Ibrance 100 mg Capsule rigide Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

ibrance 100 mg capsule rigide

pfizer ag - palbociclibum - capsule rigide - palbociclibum 100 mg, cellulosum microcristallinum, lactosum monohydricum 74.367 mg, carboxymethylamylum natricum a, silica colloidalis anhydrica, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 172 (flavum), e 171, drucktinte: lacca, e 171, ammoniae solutio 28 per centum, propylenglycolum, simeticonum, pro capsula, natrium 1.71 mg. - carcinoma della mammella - synthetika

Ibrance 125 mg Capsule rigide Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

ibrance 125 mg capsule rigide

pfizer ag - palbociclibum - capsule rigide - palbociclibum 125 mg, cellulosum microcristallinum, lactosum monohydricum 92.958 mg, carboxymethylamylum natricum a, silica colloidalis anhydrica, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 172 (flavum), e 171, drucktinte: lacca, e 171, ammoniae solutio 28 per centum, propylenglycolum, simeticonum, pro capsula, natrium 2.13 mg. - carcinoma della mammella - synthetika

CERTICAN Ιταλία - Ιταλικά - AIFA (Agenzia Italiana del Farmaco)

certican

novartis farma s.p.a. - everolimus - everolimus